Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Data include three late-breaking abstracts, underscoring Astellas’ efforts to potentially redefine expectations for patients across its oncology portfolio
Astellas Pharma will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, showcasing the company’s focus on making a meaningful difference for people living with hard-to-treat ca